Study wrapper · #1119
GLP-1 Receptor Agonist Therapy for Obesity Under Japan's Optimal Use Guideline: A Prospective Real-World Study of Lifestyle Pre-Treatment, Time-Limited Treatment Cap, and Post-Cessation Regain.
Editor's note
This is a natural experiment in what happens when a regulator forces discontinuation, and the answer is unambiguous: the weight came back fast. The six-month lifestyle prerequisite also looks counterproductive for post-surgical patients, most of whom gained weight while waiting. With 104 patients and small numbers at the later time points, the precision is limited, but the direction of the post-cessation curve is hard to argue with and speaks to obesity as a chronic condition rather than a fixed course of therapy.
Plain-language abstract
Japan reimburses GLP-1 receptor agonists for obesity only after a mandatory six-month lifestyle program, caps therapy at 68 weeks for semaglutide or 72 weeks for tirzepatide, and then requires a washout. Researchers prospectively followed 104 patients through all three phases. During the mandated lifestyle phase, patients seeking rescue after bariatric surgery actually gained weight while primary patients stayed flat. On drug, both groups lost weight similarly, reaching about -16% by the treatment endpoint. After the mandated stop, 95% regained weight within two months and the mean change reverted from -14.4% to -7.0% by month 22.